Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

Publisher： Karger

E-ISSN： 2296-5262|32|3|99-102

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.32, Iss.3, 2009-02, pp. : 99-102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

Phase I/II Study of Paclitaxel and 5-Fluorouracil as Second-Line Therapy in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 305-308

Karger

Access to resources Recommend Favorite

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 238-246

Karger

Access to resources Recommend Favorite

Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 33, Iss. 3, 2010-02 ,pp. : 89-93

Karger

Access to resources Recommend Favorite

Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study

By  

Oncology Research and Treatment, Vol. 34, Iss. 8-9, 2011-08 ,pp. : 469-470

Karger

Access to resources Recommend Favorite